A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
← catalyst calendarSponsored by Prelude Therapeutics (industry) · PRLD — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
9
Countries
Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-03 | actual | When the study began enrolling |
| Primary completion | 2026-01-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Esophageal Cancer
- Metastatic Solid Tumor
- Non-small Cell Lung Cancers
- SMARCA4 Gene Mutation
Interventions
- Drug: PRT3789
- Drug: pembrolizumab — also filed as KEYTRUDA®
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1)
measured Baseline through completion of study, an average of 2 years
Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence and severity of AEs according to NCI CTCAE (Part 1)
measured Baseline through study completion, an average of 2 years
Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Objective Response Rate (Part 2)
measured Baseline through study completion, an average of 2 years
Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Duration of Response (Part 2)
measured Baseline through study completion, an average of 2 years
Permalink · PRLD's whole pipeline · Catalyst calendar · Every registered study · What changed